Peter Sullivan

Senior Scientist - Helmholtz Institute for Pharmaceutical Research

Co-founder, MyxoTech GmbH
- Chemical diversity for a new era

[Peter Sullivan @PRFSullivan]

@AdamInHTownTX @greg_price11 Probably the most memorable during that Bulls era outside of Jordan sealing it in Utah

[Peter Sullivan @PRFSullivan]

@greg_price11 That Charles Smith sequence was glorious

[Peter Sullivan @PRFSullivan]

@AlexB_HLTW @BarackObama No one outside of US conservatism calls Obama the great divider

[Peter Sullivan @PRFSullivan]

@simonmaechling @KenDBerryMD Let's run an LCMS on that banana

[Prachee Avasthi @PracheeAC]

I confess I now think I was SO wrong about a long-held belief.

For many years, my sister was in tech and I was an academic on the defined path. I thought she was crazy switching jobs when I had a very fulfilling forever job. She moved companies every couple years and I was baffled — even though I myself felt that my greatest gains were at career transitions (undergrad to grad school, grad school to postdoc, postdoc to faculty position, untenured to tenured..the last of which was the least interesting by a mile IMO).

People often see themselves as “constantly learning” in intellectual work because they define learning as gaining new knowledge and not orthogonal skills. New knowledge is pretty much a given since most people haven’t done most things in the vast uncharted space of the unknown. But in any given role, skills get mastered and totally new challenges become more scarce even if they exist. For many, this is a feature not a bug. I get that. Hard mode for the rest of your life isn’t necessary appealing to everyone.

But if you think you’re in your profession for a lifetime of learning, it’s useful to assess whether that’s remotely true. So I’d say I’m a convert.

My updated view is that the fastest way to grow is to blow up your assumptions as frequently as you can. It’s not correct or better in some absolute sense or anything. No virtue signaling here. I just love that what we always held true can be updated. And that the biggest changes in assumptions can have the biggest impact because ALL the downstream outcomes are along for the ride.

[Peter Sullivan @PRFSullivan]

@jrkelly @FutureFetish007 As a stockholder, @jrkelly I still think Ginkgo turns things around. I was attracted to the company because it's taking on the impossible. Scaling genetic engineering changes the game.

[Peter Sullivan @PRFSullivan]

@noquakquak @EoinHiggins_ @DisabledDoctor As an American, I love the US. There is so much potential embedded in the founding principles. However, at the same time the US was helping Europe free itself of fascism, the US was enforcing segregation domestically. This seems to be glossed over in the context of WWII.

[Peter Sullivan @PRFSullivan]

@NobelPrize You seee this more frequently than you'd like. Carl Woese, Kati Kariko, and even more recently Pieter Dorrestein were similarly disregarded. It's a right of passage for a lot of great science.

[Peter Sullivan @PRFSullivan]

@PracheeAC Proud Bears fan here

[Peter Sullivan @PRFSullivan]

@Biotech2k1 This is great perspective. Appreciate it

[Peter Sullivan @PRFSullivan]

@coachgkap @rtnarch @DrNeilStone Going from having an uncontrolled fire to being able to control the fire for specific purposes is the inventive step.

[Peter Sullivan @PRFSullivan]

@ChicagoBears Bears fan now living in Germany. I was up until 6a watching this masterpiece. Best game I've seen in 40 years. BEARS!!!!

[Chicago Bears @ChicagoBears]

Not. Done. Yet.

[Peter Sullivan @PRFSullivan]

@coachgkap @rtnarch @DrNeilStone Controlled fire is

[Peter Sullivan @PRFSullivan]

@Biotech2k1 Enveda if they decide to go public. 3 candidates in the clinic with pre-clinical pipeline moving FAST

[Peter Sullivan @PRFSullivan]

@Biotech2k1 Oil and Gas seems like the wrong direction for Biotec2k

[Bruce Booth @LifeSciVC]

It’s been one of the single largest days for FOPO deal activity in biotech history.

Dec 9, 2025. $2.5B+ being raised. 7 deals.

Other big days:
May 28, 2020.  $2.0B.  5 deals
May 18, 2020.  $2.6B.  6 deals
Jan 22, 2020.  $1.3B.  7 deals
Jan 6, 2016.  $1.2B.  9 deals

[Peter Sullivan @PRFSullivan]

@Biotech2k1 Out of curiousity why maintain 0.5%?

[Peter Sullivan @PRFSullivan]

@davidycli @shelbynewsad This could apply to any type of company in any industry though

[Peter Sullivan @PRFSullivan]

@Biotech2k1 But at what point do you consider the risk of that pursuit?